Evidence map›Paper›PMID 25785641›Full record

ArticleThe Permanente journal2015

Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.

Daniela A Bota, Daniela Alexandru-Abrams, Chrystel Pretto, Florence M Hofman, Thomas C Chen, Beverly Fu, Jose A Carrillo, Virgil Ejc Schijns, Apostolos Stathopoulos

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Permanente journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Therapeutic Immunization against Glioblastoma.International journal of molecular sciences · 2018
    Review
  10. Review
  11. Tumor Vaccines for Malignant Gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Daniela A BotaAssociate Professor of Neurology and Neurosurgery at the University of California, Irvine in the City of Orange. dbota@uci.edu.
Daniela Alexandru-AbramsNeurosurgery Resident at the University of California, Irvine Medical Center in the City of Orange. danielaa@uci.edu.
Chrystel PrettoLaboratory Manager for Epitopoietic Research Corporation at the Scientific Park Crealys in Gemblous, Les Ines, Belgium. pretto@ercbelgium.eu.
Florence M HofmanProfessor of Pathology at the Keck School of Medicine, University of Southern California, Los Angeles. hofman@usc.edu.
Thomas C ChenChief Medical Officer of Epitopoietic Research Corporation and a Professor of Neurosurgery at the Keck School of Medicine, University of Southern California, Los Angeles. tcchen@usc.edu.
Beverly FuNeurological Oncology Nurse Practitioner in the Neurology Department of the University of California, Irvine Medical Center in the City of Orange. dfu@uci.edu.
Jose A CarrilloAssistant Professor of Neurology at the University of California, Irvine Medical Center in the City of Orange. carrilj2@uci.edu.
Virgil Ejc SchijnsChief Security Officer of Epitopoietic Research Corporation and a Professor of Immune Intervention in the Department of Cell Biology and Immunology at the Wageningen University in Netherlands. virgil.schijns@wur.nl.
Apostolos StathopoulosChief Executive Officer for Epitopoietic Research Corporation at the Scientific Park Crealys in Gemblous, Les Ines, Belgium and Chief Neurosurgeon, Department of Neurosurgery, Arlon Hospital, Belgium. tstath@hotmail.com.
University of California, Irvine Medical Center · USUniversity of Southern California · USDirectorate-General Joint Research Centre · BEFund for Scientific Research · BEInstitute of Immunology · HRUniversity of California, Irvine · US

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
NCATS NIH HHS UL1 TR001414
6 · The paper itself

Abstract

Glioblastoma multiforme is a highy aggressive tumor that recurs despite resection, focal beam radiation, and temozolamide chemotherapy. ERC-1671 is an experimental treatment strategy that uses the patient's own immune system to attack the tumor cells. The authors report preliminary data on the first human administration of ERC-1671 vaccination under a single-patient, compassionate-use protocol. The patient survived for ten months after the vaccine administration without any other adjuvant therapy and died of complications related to his previous chemotherapies.

Indexed as

Frontal LobeAdultAntibodies, NeoplasmBevacizumabBrain NeoplasmsGlioblastomaHumansMagnetic Resonance ImagingMaleNeoplasm Recurrence, LocalTreatment OutcomeVaccinesAntibodies, NeoplasmBevacizumabVaccines

Identifiers

PMID25785641
PMCPMC4403580
OpenAlexW2114135825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.